Best Insulin Pump : A Comprehensive Guide

A Virtual Scribe Will do your SOAP notes

Freed's AI medical scribe listens, transcribes, and writes notes for you.

*No payment information is required. Try free for 7 days

Insulin pumps are becoming increasingly popular as a way to manage diabetes, and for a good reason. Insulin pumps can provide better blood sugar control than multiple daily injections of insulin and can be much less disruptive to your life.

If you’re considering an insulin pump, there are a few things you should know. First, insulin pumps are not for everyone. They require a significant investment of time and effort to learn how to use them properly, and they’re not right for everyone with diabetes. Second, even if an insulin pump is right for you, it’s important to understand how they work and what their limitations are. Here’s a quick overview of insulin pumps.

Our Rating of the Best Insulin Pump

PumpSensor IntegrationCalibrationsSystem TypeUser InterfaceInsulin Capacity
Tandem t:slim X2Integrates with Dexcom G6None requiredHybrid closed-loopTouchscreen display300 units
Omnipod 5Integrates with Dexcom G6None requiredHybrid closed-loopTouchscreen (PDM) or smartphone app200 units
Medtronic 780GIntegrates with Guardian™ 4 sensor (with SmartGuard™ tech)None required when Guardian™ 4 & SmartGuard™ are enabledHybrid closed-loopPhysical buttons300 units
iLet Pump (Beta Bionics)*Designed to work with Dexcom G6None required in most configurations (subject to updates)Hybrid or fully closed-loop (ongoing trials)Simplified interface; minimal user inputs~300 units (TBD)

How do insulin pumps work?

An insulin pump is a small, computerized device that delivers insulin through a catheter placed just under the skin. Insulin pumps are programmed to deliver small, steady doses of insulin throughout the day (known as a basal rate), and can also give larger doses of insulin at mealtimes (bolus doses).

What are the benefits of using an insulin pump?

There are several potential benefits to using an insulin pump. These include:

  • Improved blood sugar control
  • More flexibility in your daily routine
  • Fewer low blood sugar episodes
  • Reduced risk of long-term complications from diabetes

However, it’s important to remember that insulin pumps are not a cure for diabetes, and they don’t eliminate the need for careful self-management.

What are the disadvantages of using an insulin pump?

There are also some disadvantages to using an insulin pump. These include:

  • The need for frequent blood sugar monitoring (CGMs have largely reduced the burden of frequent checks)
  • The risk of diabetic ketoacidosis if the pump is not used properly (a diabetes emergency plan is required if you are on a pump)
  • The inconvenience of wearing the pump all the time
  • The cost of the pump and supplies

The types of insulin pumps 

ManufacturerMedtronicInsuletTandem Diabetes Care
Legacy ModelsMiniMed (530G, 630G, 670G, 770G, 780G), MiniMed 508, MiniMed Paradigm (511, 512, 712, 515, 715), MiniMed Paradigm REAL-Time (522, 722), MiniMed Paradigm REAL-Time RevelOmnipod DASH, Insulet Omnipod UST400, Omnipod ErosTandem t:slim G4, Tandem t:flex
Current Model (Flagship)MiniMed™ 780G systemOmnipod 5Tandem t:slim X2
Features- Links to a CGM (Guardian™ 4 or Guardian™ 3 sensors/transmitters)- Links to Dexcom G6 CGM- Links to Dexcom G6 CGM
- Integrated pump & display- PDM (Android-based) or personal smartphone as controller- Integrated pump & display
- Smartphone app (tracks BG trends)- Tubeless pump design- Advanced algorithms (Basal IQ / Control IQ)
- Compatible with Medtronic Extended infusion set
Dimensions (inches)3.78 (L) x 2.11 (W) x 0.96 (D)2.05 (L) x 1.53 (W) x 0.57 (D)3.13 (L) x 2.0 (W) x 0.6 (D)
Compatible InsulinRapid-acting U100 insulin (Humalog®, NovoLog®)U100 insulins (Novolog, Humalog, Admelog, Fiasp)U100 insulins (Novolog, Humalog)
Basal Increment0.025, 0.05, or 0.1 units0.05 units0.1 units
(Max bolus 0–25 units)
Maximum Basal Rate0–35 units/hour (or the Max Basal Rate amount, whichever is lower)30 units/hour15 units/hour
Maximum BolusStandard speed: 1.5 units/min30 units25 units
Quick speed: 15 units/min
Reservoir/Pod Capacity300 units200 units300 units
Battery Life- Requires 1 AA (1.5 V) battery- Rechargeable lithium battery- Rechargeable lithium battery
- Recommends AA lithium (FR6) or AA alkaline (LR6)- Android phone as PDM (separate battery management)- Typically up to 7 days of operation (depends on settings)
- Accepts NiMH rechargeables
Basal ProgrammingThree basal patterns12 basal patterns6 basal patterns
Insulin on BoardYesYesYes
SmartGuard™ tech available for users needing 8–250 units/daySmartAdjust technologyControl IQ / Basal IQ technology
CGM IntegrationYesYesYes
(Guardian™ 4 sensor, changed every 7 days)(Dexcom G6 and G7)(Dexcom G6 and G7)
Calibration of CGMNot required when using Guardian™ 4 sensor with SmartGuard™ techNoNo
Future ModelN/AN/ATandem Mobi (tubeless pump)
Tandem t:slim X3 (bolus via smartphone; FDA-cleared Feb 16, 2022)
Major LimitationUser is tethered to tubingLimited to 200 units of insulin per podUser is tethered to tubing
Major Advantage- Hybrid-closed loop system- Hybrid-closed loop system- Hybrid-closed loop system
- Meal Detection™ feature- Tubeless design- Advanced algorithms reduce burden
- 7-day Extended infusion set option

How do I choose an insulin pump?

If you’re thinking about using an insulin pump, talk to your doctor or diabetes educator. They can help you decide if an insulin pump is right for you and, if so, which type of pump would be best. Once you’ve decided to use an insulin pump, you’ll need to choose a pump that’s right for you. There are many different brands and models of insulin pumps available, so it’s important to do your research before making a decision.

Considerations when choosing an insulin pump include:

  • Ease of use: Some pumps are easier to use than others. Be sure to get a demonstration of the pump before you buy it.
  • Cost: Insulin pumps are expensive, so be sure to find out what your insurance will cover.
  • Size and weight: Insulin pumps come in different sizes and weights. Consider how easy the pump will be to carry with you throughout the day.
  • Battery life: Insulin pumps run on batteries, so you’ll need to know how long the pump can run on a single charge.
  • Features: Insulin pumps have different features, such as the ability to give bolus doses of insulin at mealtimes or to suspend insulin delivery when blood sugar is low. Consider which features are most important to you.

Choosing the best insulin pump

When it comes to insulin pumps, there is no one-size-fits-all solution. The best pump for you will depend on your individual needs and preferences. However, there are some factors that you should keep in mind when choosing a pump. First, consider the size of the pump. If you are active or frequently on the go, you may prefer a smaller, more compact pump. Second, think about the features that are important to you. Some pumps offer more advanced features than others, such as bolus calculators and wireless connectivity. Finally, be sure to consult with your healthcare team to ensure that the pump you choose is compatible with your insurance coverage. With all of these factors in mind, you can be sure to find the best insulin pump for your needs.

Tandem T Slim X2

The Tandem T slim X2 insulin pump is a state-of-the-art device that offers users the latest in diabetes technology. The pump features control IQ, which automatically adjusts basal insulin delivery to keep blood sugar levels in target range. In addition, the pump is a hybrid closed loop system, meaning that it can be used with compatible continuous glucose monitors (Dexcom G6) to improve control further.

FeatureComment
Time in range (70–180 mg/dL)The Control IQ system helps prevent extreme glucose readings.
Ease of placing pump commands (bolus entries)Commands are entered via a colored and responsive touch screen.
Water resistanceWatertight up to 3 feet (approximately 1 meter) for up to 30 minutes.
Effect of elevation above sea levelInsulin delivery may be interrupted in low atmospheric pressure (e.g., at altitudes above 10,000 feet or during takeoff).
Integration with other devicesBluetooth connectivity allows linking to smartphones and CGMs.
Tethered tubingTubing can get caught on clothing or other objects.
Battery lifeTypically requires recharging every 7 days (maximum), depending on usage.
Risk of inadvertent entriesThe unlock procedure helps prevent accidental insulin boluses.

Omnipod 5

The Omnipod 5 Insulin Pump is a small, wearable insulin pump that provides a convenient and discreet way to manage diabetes. The pump can be worn on the body for up to three days at a time, and it is waterproof, so it can be worn during activities such as swimming or showering. The pump delivers insulin through a small plastic tube (cannula) that is inserted just under the skin. The pump automatically delivers insulin based on the user’s glucose levels, and it can also be manually adjusted to provide bolus doses of insulin before meals or snacks. The Omnipod 5 Insulin Pump is an easy-to-use and effective way to manage diabetes, and it offers a convenient and discreet alternative to traditional insulin pumps.

FeatureComment
Time in range (70-180mg/dl)SmartAdjust Technology is a hybrid closed loop system
Ease of placing pump commands (bolus entries etc)Entries via a simple touch screen of a separate handheld android smart device.
Water resistanceWaterproof for depths up to 25 feet for up to 60 minutes. It has IP28 certification
Effect of Elevation above sea levelInterruption in insulin delivery can occur at low atmospheric pressures (mountain climbing above 10,000 feet or take-off during air travel)
Integration with other devicesBluetooth connectivity to phones and CGMs. Insulin pump can be controlled via either an Insulet-provided controller or a compatible phone (using the Omnipod 5 app)
Tethered TubingThis is a tubeless pump. Some users love this feature.
Battery lifeRecharge of lithium battery in Insulet-provided controller or a compatible phone
Risk of inadvertent entriesThe unlock procedure prevents accidental insulin boluses

Medtronic Minimed 780G

The Medtronic MiniMed™ 780G system is an insulin pump that utilizes advanced features to help people with diabetes manage their condition. The pump is capable of delivering insulin in small doses throughout the day, or it can automatically deliver a large bolus of insulin at mealtimes. The pump is designed with Meal Detection™ technology, which detects a rapid rise of blood sugar levels, typical during mealtimes, and pushing a correction dose. The pump is also able to automatically adjust insulin delivery based on the user’s blood sugar levels. The MiniMed™ 780G system also features a CGM (Continuous Glucose Monitor) that continuously monitors the user’s blood sugar levels and sends alerts to the pump if those levels get too high or too low. The system also comes with a smartphone app that allows users to track their blood sugar levels, insulin delivery, and other important data.

FeatureComment
Time in range (70-180mg/dl)SmartGuard™ technology is a hybrid closed loop system. Fingersticks required in manual mode and to enter SmartGuard™. Pivotal trial participants spend avg of > 93% in SmartGuard™.
Ease of placing pump commands (bolus entries etc)Hard tactile physical buttons and a complex menu (learning curve)
Water resistanceWaterproof for depths up to 12 feet for up to 24 hours (when the reservoir and tubing are properly inserted)
Effect of Elevation above sea levelInterruption in insulin delivery can occur at low atmospheric pressures (mountain climbing above 10,150 feet)
Integration with other devicesBluetooth connectivity to smart phones, CGMs, and select Apple Watches®.
Tethered TubingTubing may get caught on clothing etc.
Battery lifeStandard AA battery life
Risk of inadvertent entriesThe unlock procedure prevents accidental insulin boluses

The Verdict

Tandem T Slim X2

The Tandem T Slim X2 is arguably the best hybrid closed loop system on the market. It integrates with the Dexcom G6 CGM (the current gold standard of continuous glucose monitoring) which means no fingersticks. The control IQ keeps you in range.

tandem t slim x2

Omnipod 5

The SmartAdjust technology is Insulet’s new hybrid closed loop system which is fully integrated with Dexcom G6. It is the third hybrid-closed loop system on the market. The absence of a tubing makes it appealing to some patients (e.g. athletes). Users of this pump type have more “real estate” in terms of their preferred site of pump placement. This can be advantageous in patients with significant scar tissue (lipohypertrophy), since alternate sites can be readily utilized without the inconvenience of being tethered to an infusion set.

Omnipod 5

Medtronic Minimed 780G

The current version of medtronic’s Minimed series, the Minimed 780G is an excellent hybrid closed loop system. Multiple or daily calibrations are no longer needed when using the Guardian™ 4 sensor with SmartGuard™ technology. Alerts issues from 770G have been addressed and are significantly less frequent. This is a huge improvement on previous versions of this pump, placing it on par with both the Tandem T slim X2 and Omnipod 5 pumps in terms of ease of use. The meal detection technology is a revolutionary feature that helps mitigate periods of significant postprandial hyperglycemia. As practicing endocrinologists, we have received very good feedback from patients who have switched to the current Minimed 780G pump.

 

Selecting a personalized insulin pump

We have developed this simple tool to help you select the right insulin pump for you. There are three simple questions. Are you willing to check your blood sugar twice a day? Do you prefer a tubed or tubeless pump and finally, how many units of insulin do you require a day. This tool is based on a well thought out algorithm based on feedback from patients, diabetes educators and diabetes care specialists.

choosing the right insulin pump

Insulin Pump Recommendation Tool

Provide three responses and get a personalized feedback in less than 5 seconds. 


Not at all Likely Extremely Likely

Who can get an insulin pump?

Based on the current medicare guidelines in 2023, patients with type 1 diabetes mellitus and type 2 diabetes patients on an intensive multiple daily insulin injection regimen qualify for insulin pump therapy.

The decision to use an insulin pump as part of diabetes management is an individual one, and should be made in consultation with a healthcare provider. However, there are some general guidelines for who may be a good candidate for an insulin pump:

  1. Type 1 diabetes: Insulin pumps are typically used by people with type 1 diabetes who require insulin to manage their blood sugar levels.
  2. Intensive insulin therapy: Insulin pumps are generally used for people who require intensive insulin therapy, which means taking multiple daily injections of insulin or using a basal-bolus insulin regimen.
  3. Self-management skills: Insulin pump therapy requires a high level of self-management skills, including the ability to perform blood glucose monitoring and calculate insulin doses.
  4. Motivation and willingness to learn: Insulin pump therapy also requires a high level of motivation and willingness to learn about the device and its use.
  5. Financial coverage: Insulin pumps can be expensive, and may not be covered by insurance or other healthcare plans. People who are interested in using an insulin pump should check with their insurance provider to see if it is covered and what the cost may be.

In addition to these general guidelines, there may be specific medical considerations that need to be taken into account when deciding whether insulin pump therapy is appropriate. This includes factors such as pregnancy, age, and other health conditions.

It is important to note that insulin pumps are not appropriate for everyone with diabetes, and not everyone will benefit from this type of therapy. Your healthcare provider can help you determine if insulin pump therapy is right for you, and can provide guidance on how to use the device and manage your diabetes effectively.

What does a hybrid closed-loop insulin pump mean?

The term “hybrid” in the context of the hybrid closed loop insulin pump refers to the combination of a continuous glucose monitor (CGM) and an insulin pump. The system is considered “closed loop” because the CGM and insulin pump are integrated and work together to automate insulin delivery. However, the system is not fully closed loop, as it still requires some manual input from the user.

The system is also referred to as an “artificial pancreas” because it mimics the function of the pancreas in delivering insulin to the body. The hybrid closed loop system uses the CGM to measure blood glucose levels in real-time, and the insulin pump uses an algorithm to calculate the appropriate amount of insulin to deliver based on the glucose levels, rate of glucose and the estimated insulin sensitivity factor of the individual.

Benefits

The hybrid closed-loop system has several benefits over traditional insulin pumps, including:

  1. Improved glucose control: The hybrid closed-loop system can help to maintain stable blood glucose levels, which can reduce the risk of long-term complications associated with diabetes.
  2. Reduced risk of hypoglycemia: The algorithm used by the hybrid closed-loop system is designed to minimize the risk of hypoglycemia by automatically adjusting insulin delivery based on glucose levels.
  3. Flexibility: The hybrid closed-loop system allows for more flexibility in daily activities, as the system can adjust insulin delivery based on changes in activity or food intake.
  4. Ease of use: The hybrid closed loop system is designed to be user-friendly and easy to operate, with a simple interface and automated features.

Limitations

The hybrid closed loop system also has some limitations, including:

  1. Cost: The hybrid closed loop system can be expensive, and may not be covered by insurance or other healthcare plans.
  2. Training: The system requires specialized training to use effectively, and may not be appropriate for individuals who are not able to learn how to use it.
  3. Maintenance: The system requires regular maintenance, including changing infusion sets and sensors, which can be time-consuming and require additional supplies.

Progress Toward an Artificial Pancreas

For many years, real-time continuous glucose monitoring (RT-CGM) and insulin pumps functioned separately, requiring users to interpret CGM readings themselves and manually adjust insulin doses. The ultimate goal is to replicate the pancreas’s natural ability to secrete insulin in response to blood glucose fluctuations, creating what is often termed an “artificial pancreas.” Such a system consists of a continuous glucose sensor, an automated insulin-delivery mechanism, a control algorithm linking sensor data to insulin output, and a way to display glucose levels in real time. Barriers to full automation include limited sensor accuracy, the time lag between rapid-acting insulin administration and its physiological effect, and the many daily factors—from meals and exercise to menstrual cycles and acute illness—that change insulin requirements. Still, each incremental improvement reduces the burden on people with diabetes.

One of the earliest advances was the low glucose (threshold) suspend feature, which halts insulin delivery when sensor glucose drops below a preset level. Although this does not fully prevent lows caused by incorrect insulin dosing or missed carbohydrates, it helps reduce the severity of hypoglycemia if a user does not respond to alarms. Systems evolved further with suspend-before-low technology, predicting an oncoming low and pausing insulin in advance. After glucose recovers, normal insulin delivery resumes automatically, lowering the risk of severe hypoglycemia with minimal user intervention.

A larger leap came with hybrid closed-loop (HCL) systems, where the insulin pump increases or decreases basal insulin rates in response to sensor glucose values, but users still deliver boluses before meals. This approach is especially useful for stabilizing glucose during fasting periods or overnight. To make the most of these systems, users typically still need to pre-bolus for meals, be mindful of exercise, and follow guidelines for treating oncoming hypoglycemia. Though HCL lessens some of the mental effort of managing diabetes, a fully closed-loop solution—one that handles both basal needs and mealtime spikes—remains challenging because current rapid-acting insulin does not match real-time glucose fluctuations quickly enough. Looking further ahead, dual-hormone configurations that add substances like glucagon or amylin may better replicate a healthy pancreas’s ability to both lower and raise blood glucose levels.

The long-term safety, affordability, and effectiveness of fully automated approaches are still under investigation. Yet many people affected by diabetes have pushed for faster progress through the #WeAreNotWaiting movement, which led to do-it-yourself systems that integrate commercially available pumps, CGMs, and open-source software. Although these user-driven technologies have shown promising results in reducing average glucose levels and boosting time in range, they operate outside the traditional regulatory framework, raising safety and liability questions. Some developers have recently sought regulatory clearance for open-source platforms, resulting in new FDA-approved applications like Tidepool Loop. Early data suggest do-it-yourself or open-source systems can further improve glucose management compared to standard sensor-augmented pumps, but healthcare teams must balance the benefits of rapid innovation with concerns about proper oversight and reliable support.

It is likely that progress toward an artificial pancreas will continue in small but meaningful steps. Early threshold-suspend features have already reduced nighttime hypoglycemia, while suspend-before-low systems and hybrid closed loops offer increasingly hands-off solutions. Although these partial-automation approaches can introduce additional alarms or technical demands, many users and research studies highlight how they improve glycemic stability, reduce the immediate risk of severe events, and potentially ease the emotional and logistical burden of diabetes. As sensor accuracy improves, faster or smarter insulin formulations enter the market, and automated algorithms adapt to individual patterns, the dream of a fully closed-loop system—capable of handling mealtimes, exercise, and everything in between—draws ever closer.

Closed-Loop Control (CLC) Insulin Delivery

Fully automated, or “closed-loop,” insulin delivery depends on algorithm-based insulin adjustments, which introduce added layers of safety considerations. While overnight insulin management in these systems tends to be straightforward, controlling post-meal glucose levels and accounting for exercise remain the most difficult challenges. Historically, most randomized trials of closed-loop technology have been small and short term, often conducted under highly controlled conditions.


iLet Bionic Pancreas

Approved by the FDA in 2023, the iLet Bionic Pancreas takes a step closer to fully automated insulin delivery. Instead of requiring precise carbohydrate counting, users only classify each meal as small, medium, or large. The system also initializes insulin settings based on the individual’s body weight. A 13-week multicenter randomized study involving 219 adults with type 1 diabetes showed that the iLet led to a greater reduction in A1C (−0.5%, 95% CI −0.6 to −0.3; p < 0.001) compared to standard care, without any significant increase in hypoglycemia.


Other Automated Insulin Delivery Systems

A range of closed-loop approaches have emerged, employing either a single hormone (rapid-acting insulin) or a dual-hormone strategy (insulin plus glucagon) to more closely mimic normal physiology. Evidence remains insufficient to identify a single best approach or algorithm. Common algorithm designs include:

  • Model Predictive Control (MPC): Predicts future glucose levels and adjusts insulin accordingly.
  • Proportional Integral Derivative (PID): Calculates insulin delivery based on how far current glucose deviates from a target.
  • Fuzzy Logic (FL): Uses rule-based logic that emulates clinical decision making.

Multiple meta-analyses underscore the effectiveness of artificial pancreas systems. In one review of 40 randomized trials (1,027 individuals with type 1 diabetes), there was a notable 9.6% increase in time spent within the 70–180 mg/dL range, along with reduced high and low glucose events, regardless of whether single or dual hormones were used. Another meta-analysis involving 24 studies (585 participants) showed a 12.6% improvement in time in range for artificial pancreas systems overall, with dual-hormone systems achieving better outcomes than single-hormone setups. Longer-duration studies (at least eight weeks) confirm these findings, and a meta-analysis in 504 children similarly found improved time in range in both single- and dual-hormone closed-loop approaches, with dual-hormone setups offering additional advantages.

Comparison of CLC (Closed-Loop Control) Systems

FeatureMedtronic 670G/770GMedtronic 780GTandem t:slim with Control IQOmnipod 5iLet Bionic Pancreas
Insulin DeliveryTubingTubingTubingTubeless (Pod)Tubing
CGMGuardian™ 3Guardian™ 4Dexcom G6Dexcom G6Dexcom G6
Reservoir Capacity300300300200180
(units)
Calibration NeededYesNoNoNoNo
SuppliesDME companyDME companyDME companyPharmacyTo be determined
Control via SmartphoneData viewable from smartphoneData viewable from smartphoneSmartphone bolus capabilityCompatible smartphone controllerNo
Algorithm Initiation48 hrs in Manual Mode to estimate TDI48 hrs in Manual Mode to estimate TDIWeight & TDI entry with max 50% TDI over 2 hrTDI estimated from programmed basal ratesWeight entry
Bolus AutomationNoYes, every 5 min; up to 1 auto-correct bolus/hr if BG predicted >180NoUnknownUnknown
Other InputsCIR, AITUnable to override bolus doseCIR, ISF, AIT fixed at 5 hoursCIR, ISF, AIT; bolus calculator uses CGM rate of change“Usual for Me,” “More,” or “Less” (custom meal sizing)
Extended BolusNoNoYes (up to 2 hours)NoNo
Algorithm AdjustmentEvery 6 daysEvery 6 daysTDI scales basal changesEvery 3 days (pod change)Continuously or based on updated weight
Target120 mg/dL100, 110, or 120 mg/dL112.5–160 mg/dL110, 120, 130, 140, 150 mg/dL (customizable by time of day)100, 110, 120, 130 mg/dL (customizable by time of day)
ExerciseTemp target 150 mg/dL for 2–12 hrsTemp target 150 mg/dL for 2–12 hrsExercise target 140–160 mg/dL (cannot program duration)“Sleep Mode” targets 112.5–120 mg/dL without auto-bolus; can set target 150 mg/dL (“less aggressive”) for 1–24 hrsNone
Safety Mode*Yes; forced exits from HCLYes; exits to “Safe Basal” up to 4 hrs; 5.7 vs. 1.7 exits/week vs 670GNot applicable (defaults to manual basal settings)Yes; forced exits are “rare”Yes; “BG-run mode” uses manually entered BG up to 72 hrs, forcing switch to alternate therapy

Abbreviations & Notes:

  • TDI: Total Daily Insulin
  • CIR: Carb-to-Insulin Ratio
  • ISF: Insulin Sensitivity Factor
  • AIT: Active Insulin Time (duration insulin is considered active)
  • HCL: Hybrid Closed Loop
  • *Safety Mode** refers to a fallback or “safe basal” mode when the system cannot run closed-loop (e.g., sensor failures, exceeding limits, or user override).
  • Insulin delivery and CGM pairing may vary by region and specific device model. Be sure to verify local regulatory approvals and product instructions.

References

  1. Collyns OJ, Meier RA, Betts ZL, Chan DSH, Frampton C, Frewen CM, et al. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes. Diabetes Care. 2021 Feb 12;44(4):969–75.
  2. Medtronic announces latest data on MiniMedTM 780G system with the newest GuardianTM 4 sensori at American Diabetes Association 82nd Scientific Sessions [Internet]. Medtronic News. [cited 2022 Dec 5]. Available from: https://news.medtronic.com/Medtronic-Announces-Latest-Data-on-MiniMed-TM-780G-system-with-the-newest-Guardian-TM-4-sensor-at-American-Diabetes-Association-82nd-Scientific-Sessions
  3. American Diabetes Association Professional Practice Committee; Summary of Revisions: Standards of Medical Care in Diabetes—2022Diabetes Care 1 January 2022; 45 (Supplement_1): S4–S7. https://doi.org/10.2337/dc22-Srev

Disclaimer

The opinions expressed here represent the views of a practicing hormone specialist (endocrinologist) and must not substitute the advice of your health care provider. This blog post is written for a non-medical audience interested in learning more about hormonal disorders. The author has no commercial conflicts of interest to declare. Also, read our privacy policy.

About the Author MyEndoConsult

The MyEndoconsult Team. A group of physicians dedicated to endocrinology and internal medicine education.

Get Freed Medical Scribe
{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}
>